
Donelly Andrew van Schalkwyk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5924931/publications.pdf Version: 2024-02-01



DONELLY ANDREW VAN

#	Article	IF	CITATIONS
1	Semi-Synthetic Analogues of Cryptolepine as a Potential Source of Sustainable Drugs for the Treatment of Malaria, Human African Trypanosomiasis, and Cancer. Frontiers in Pharmacology, 2022, 13, .	3.5	3
2	The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957. Scientific Reports, 2021, 11, 1888.	3.3	10
3	Failure of rapid diagnostic tests in Plasmodium falciparum malaria cases among travelers to the UK and Ireland: Identification and characterisation of the parasites. International Journal of Infectious Diseases, 2021, 108, 137-144.	3.3	12
4	Ex vivo susceptibility to new antimalarial agents differs among human-infecting Plasmodium species. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 5-11.	3.4	5
5	Clinical management of Plasmodium knowlesi malaria. Advances in Parasitology, 2021, 113, 45-76.	3.2	15
6	The <i>Plasmodium falciparum</i> Artemisinin Susceptibility-Associated AP-2 Adaptin μ Subunit is Clathrin Independent and Essential for Schizont Maturation. MBio, 2020, 11, .	4.1	27
7	Novel Endochin-Like Quinolones Exhibit Potent <i>In Vitro</i> Activity against Plasmodium knowlesi but Do Not Synergize with Proguanil. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	12
8	A novel multiplex qPCR assay for detection of Plasmodium falciparum with histidine-rich protein 2 and 3 (pfhrp2 and pfhrp3) deletions in polyclonal infections. EBioMedicine, 2020, 55, 102757.	6.1	41
9	Plasmodium knowlesi exhibits distinct in vitro drug susceptibility profiles from those of Plasmodium falciparum. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 93-99.	3.4	25
10	Modification of <i>pfap2μ</i> and <i>pfubp1</i> Markedly Reduces Ring-Stage Susceptibility of Plasmodium falciparum to Artemisinin <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2019, 64, .	3.2	45
11	Transient temperature fluctuations severely decrease P. falciparum susceptibility to artemisinin in vitro. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 23-26.	3.4	14
12	Clinical Validation of a Commercial LAMP Test for Ruling out Malaria in Returning Travelers: A Prospective Diagnostic Trial. Open Forum Infectious Diseases, 2018, 5, ofy260.	0.9	19
13	<i>pfk13</i> -Independent Treatment Failure in Four Imported Cases of Plasmodium falciparum Malaria Treated with Artemether-Lumefantrine in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	91
14	Comparison of the susceptibility of Plasmodium knowlesi and Plasmodium falciparum to antimalarial agents. Journal of Antimicrobial Chemotherapy, 2017, 72, 3051-3058.	3.0	32
15	Paperâ€Origamiâ€Based Multiplexed Malaria Diagnostics from Whole Blood. Angewandte Chemie - International Edition, 2016, 55, 15250-15253.	13.8	125
16	We must go for gold in public health: Table 1. BMJ, The, 2016, 354, i5138.	6.0	0
17	Degradation of Artemisinin-Based Combination Therapies Under Tropical Conditions. American Journal of Tropical Medicine and Hygiene, 2016, 94, 993-1001.	1.4	18
18	Verapamil-Sensitive Transport of Quinacrine and Methylene Blue via the <i>Plasmodium falciparum</i> Chloroquine Resistance Transporter Reduces the Parasite's Susceptibility to these Tricyclic Drugs. Journal of Infectious Diseases, 2016, 213, 800-810.	4.0	22

Donelly Andrew van

#	Article	IF	CITATIONS
19	Malaria resistance to non-artemisinin partner drugs: how to reACT. Lancet Infectious Diseases, The, 2015, 15, 621-623.	9.1	16
20	The Mu Subunit of Plasmodium falciparum Clathrin-Associated Adaptor Protein 2 Modulates <i>In Vitro</i> Parasite Response to Artemisinin and Quinine. Antimicrobial Agents and Chemotherapy, 2015, 59, 2540-2547.	3.2	42
21	Identification and Deconvolution of Cross-Resistance Signals from Antimalarial Compounds Using Multidrug-Resistant Plasmodium falciparum Strains. Antimicrobial Agents and Chemotherapy, 2015, 59, 1110-1118.	3.2	34
22	1H-NMR metabolite profiles of different strains of <i>Plasmodium falciparum</i> . Bioscience Reports, 2014, 34, e00150.	2.4	22
23	Directional Selection at the pfmdr1, pfcrt, pfubp1, and pfap2mu Loci of Plasmodium falciparum in Kenyan Children Treated With ACT. Journal of Infectious Diseases, 2014, 210, 2001-2008.	4.0	108
24	Studies with the <i>Plasmodium falciparum</i> hexokinase reveal that PfHT limits the rate of glucose entry into glycolysis. FEBS Letters, 2013, 587, 3182-3187.	2.8	19
25	Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malaria Journal, 2013, 12, 320.	2.3	36
26	Loss of pH Control in Plasmodium falciparum Parasites Subjected to Oxidative Stress. PLoS ONE, 2013, 8, e58933.	2.5	26
27	Differential Drug Efflux or Accumulation Does Not Explain Variation in the Chloroquine Response of Plasmodium falciparum Strains Expressing the Same Isoform of Mutant PfCRT. Antimicrobial Agents and Chemotherapy, 2011, 55, 2310-2318.	3.2	14
28	Inhibition of Plasmodium falciparum pH regulation by small molecule indole derivatives results in rapid parasite death. Biochemical Pharmacology, 2010, 79, 1291-1299.	4.4	38
29	Pantothenate Utilization by Plasmodium as a Target for Antimalarial Chemotherapy. Infectious Disorders - Drug Targets, 2010, 10, 200-216.	0.8	39
30	The Inhibitory Effect of 2-Halo Derivatives of d-Glucose on Glycolysis and on the Proliferation of the Human Malaria Parasite Plasmodium falciparum. Journal of Pharmacology and Experimental Therapeutics, 2008, 327, 511-517.	2.5	45
31	Feedback Inhibition of Pantothenate Kinase Regulates Pantothenol Uptake by the Malaria Parasite. Journal of Biological Chemistry, 2007, 282, 25395-25405.	3.4	19
32	Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resistance Updates, 2006, 9, 211-226.	14.4	69
33	Reversal of chloroquine resistance in Plasmodium falciparum by 9H-xanthene derivatives. International Journal of Antimicrobial Agents, 2005, 26, 170-175.	2.5	40
34	Antimalarial Quinolines and Artemisinin Inhibit Endocytosis in Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2004, 48, 2370-2378.	3.2	90
35	In Vitro Antimalarial Activity of a Series of Cationic 2,2â€~-Bipyridyl- and 1,10-Phenanthrolineplatinum(II) Benzoylthiourea Complexes. Journal of Medicinal Chemistry, 2004, 47, 2926-2934.	6.4	93
36	Plasmodium falciparum expresses a multidrug resistance-associated protein. Biochemical and Biophysical Research Communications, 2004, 321, 197-201.	2.1	54

Donelly Andrew van

#	Article	IF	CITATIONS
37	Exploring the potential of xanthene derivatives as trypanothione reductase inhibitors and chloroquine potentiating agents. Tetrahedron, 2003, 59, 2289-2296.	1.9	161
38	Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochemical Journal, 2002, 365, 343-347.	3.7	253
39	Reversal of Chloroquine Resistance in <i>Plasmodium falciparum</i> Using Combinations of Chemosensitizers. Antimicrobial Agents and Chemotherapy, 2001, 45, 3171-3174.	3.2	36
40	New amine and urea analogs of ferrochloroquine: synthesis, antimalarial activity in vitro and electrochemical studies. Tetrahedron Letters, 2000, 41, 6231-6235.	1.4	73